These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 22880843

  • 21. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H, Nakagawa H, Japanese Infliximab Study investigators.
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [Abstract] [Full Text] [Related]

  • 22. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
    Papp K, Menter A, Poulin Y, Gu Y, Sasso EH.
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586
    [Abstract] [Full Text] [Related]

  • 23. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH.
    J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
    [Abstract] [Full Text] [Related]

  • 24. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S, Mizuno K, Adachi M.
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [Abstract] [Full Text] [Related]

  • 25. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.
    Saurat JH, Langley RG, Reich K, Unnebrink K, Sasso EH, Kampman W.
    Br J Dermatol; 2011 Aug; 165(2):399-406. PubMed ID: 21564071
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [Abstract] [Full Text] [Related]

  • 27. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Jun; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 28. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R, Unnebrink K, Valdecantos WC.
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 31. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [Abstract] [Full Text] [Related]

  • 32. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
    Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.
    J Am Acad Dermatol; 2010 May; 62(5):812-8. PubMed ID: 20219265
    [Abstract] [Full Text] [Related]

  • 33. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [Abstract] [Full Text] [Related]

  • 34. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P.
    Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
    [Abstract] [Full Text] [Related]

  • 35. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C, Kirby B, Collins P, Rogers S.
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [Abstract] [Full Text] [Related]

  • 36. Treatment goals for moderate to severe psoriasis: an Australian consensus.
    Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S, Soyer HP, Wu J, Chan J, Nash P, Rawlin M, Radulski B, Foley P.
    Australas J Dermatol; 2013 May; 54(2):148-54. PubMed ID: 23330815
    [Abstract] [Full Text] [Related]

  • 37. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [Abstract] [Full Text] [Related]

  • 38. Infliximab for the treatment of adults with psoriasis.
    Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [Abstract] [Full Text] [Related]

  • 39. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM.
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [Abstract] [Full Text] [Related]

  • 40. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C.
    Acta Derm Venereol; 2019 Oct 01; 99(11):971-977. PubMed ID: 31240322
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.